尿生物标志物TIMP2与IGFBP7可识别心脏骤停后发生严重急性肾损伤的患者:一项前瞻性多中心研究
这项前瞻性多中心研究在法国3个ICU纳入115例心脏骤停患者,评估心脏骤停后中位240分钟尿[TIMP-2]*[IGFBP7]对48小时内严重AKI(KDIGO 3期)的预测价值。32例(28%)发生严重AKI,其中11例需要肾脏替代治疗。发生严重AKI者基线[TIMP-2]*[IGFBP7]中位数1.57 (ng/ml)2/1000,显著高于未发生者的0.17 (ng/ml)2/1000(p<0.001)。基线[TIMP-2]*[IGFBP7]预测严重AKI的AUC为0.91,最佳界值0.39 (ng/ml)2/1000时敏感性97%、特异性72%;界值2.0 (ng/ml)2/1000时特异性98%。其判别力显著优于基线血肌酐(AUC 0.73,p=0.005),与基线尿量相比略优但未达统计学显著(AUC 0.86,p=0.08);与血肌酐和尿量联合可显著改善后两者的预测性能。作者结论认为该标志物可有效识别严重AKI风险,低于界值0.39 (ng/ml)2/1000时严重AKI风险低。
要点
- 心脏骤停后中位240分钟尿[TIMP-2]*[IGFBP7]预测48小时内KDIGO 3期AKI的AUC为0.91(95%CI 0.84-0.95)。
- 最佳界值0.39 (ng/ml)2/1000时敏感性97%(95%CI 84-100)、特异性72%(95%CI 61-82);界值2.0 (ng/ml)2/1000时特异性98%(95%CI 92-100)。
- 发生严重AKI者基线[TIMP-2]*[IGFBP7]中位数1.57 (ng/ml)2/1000,未发生者0.17 (ng/ml)2/1000(p<0.001)。
- 基线[TIMP-2]*[IGFBP7]判别力显著优于基线血肌酐(AUC 0.73,p=0.005),与基线尿量(AUC 0.86)相比略优但未达统计学显著(p=0.08)。
- 基线[TIMP-2]*[IGFBP7]与基线血肌酐和尿量联合可显著改善后两者的预测性能。
适用人群与场景
- 法国3个ICU收治的心脏骤停后患者,共分析115例。
- 心脏骤停后中位240分钟(IQR 169-315)采集尿标本进行检测。
诊断标准与关键阈值
- 严重AKI定义为KDIGO 3期,发生在入ICU后48小时内。
- 尿[TIMP-2]*[IGFBP7]最佳界值0.39 (ng/ml)2/1000,敏感性97%、特异性72%。
- 界值2.0 (ng/ml)2/1000时特异性98%(95%CI 92-100)。
研究设计与关键结果
- 前瞻性多中心研究,法国3个ICU,115例心脏骤停患者,32例(28%)发生严重AKI,其中11例需要肾脏替代治疗。
- 发生严重AKI者基线[TIMP-2]*[IGFBP7]中位数1.57 (ng/ml)2/1000(IQR 0.80-6.62),未发生者0.17 (ng/ml)2/1000(IQR 0.05-0.59),p<0.001。
- 基线[TIMP-2]*[IGFBP7]预测严重AKI的AUC 0.91(95%CI 0.84-0.95),最佳界值0.39 (ng/ml)2/1000,敏感性97%(95%CI 84-100),特异性72%(95%CI 61-82)。
- 界值2.0 (ng/ml)2/1000时特异性98%(95%CI 92-100)。
- 基线[TIMP-2]*[IGFBP7]判别力显著优于基线血肌酐(AUC 0.73,95%CI 0.63-0.84;p=0.005),与基线尿量(AUC 0.86,95%CI 0.78-0.94)相比略优但未达统计学显著(p=0.08)。
- 基线[TIMP-2]*[IGFBP7]与基线血肌酐和尿量联合可显著改善后两者的预测性能。
证据类型、等级与局限
- 证据类型:前瞻性多中心研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为尿[TIMP-2]*[IGFBP7]可有效识别严重AKI风险患者;低于界值0.39 (ng/ml)2/1000时严重AKI风险低。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
AIM: To determine whether the urine biomarkers tissue inhibitor of metalloproteinases-2 (TIMP-2) and insulin-like growth factor-binding protein 7 (IGFBP7) can identify patients who will develop severe acute kidney injury (AKI) soon after cardiac arrest.
METHODS: We performed a prospective, multicentre study in three French ICUs. The performance of [TIMP-2]*[IGFBP7] was assessed for urine samples collected a median [IQR] of 240 [169-315] minutes post-collapse. The primary end-point was severe AKI (KDIGO stage 3), within 48 h of admission.
RESULTS: Of the 115 patients analyzed, 32 (28%) developed severe AKI. Eleven of these required renal replacement therapy. The median [IQR] baseline [TIMP-2]*[IGFBP7] level was higher in patients who developed severe AKI (1.57 [0.80-6.62] (ng/ml)2/1000) than in those who did not (0.17 [0.05-0.59] (ng/ml)2/1000; p < 0.001). The baseline [TIMP2]*[IGFBP7] predicted -severe AKI with an area under the curve [95% confidence interval (CI)] of 0.91 [0.84-0.95], an optimal cut-off value of 0.39 (ng/ml)2/1000, a sensitivity [95%CI] of 97% [84-100], and a specificity of 72% [61-82]. A cut-off of 2.0 (ng/ml)2/1000 yielded a specificity of 98% [92-100]. For predicting severe AKI, baseline [TIMP-2]*[IGFBP7] was significantly more discriminant than baseline SCr (AUC [95%CI]: 0.73 [0.63-0.84]; p = 0.005), and slightly but not significantly more discriminant than baseline UO (AUC [95%CI]: 0.86 [0.78‒0.94], p = 0.08) Combining the baseline [TIMP2]*[IGFBP7] with baseline SCr and UO significantly improved the latter markers' predictive performance.
CONCLUSION: Urine [TIMP-2]*[IGFBP7] effectively identify patients with a risk of severe AKI. Below a cut-off of 0.39 (ng/ml)2/1000, the risk of severe AKI is low.
参考来源
- Titeca-Beauport D, Daubin D, Chelly J, et al. The urine biomarkers TIMP2 and IGFBP7 can identify patients who will experience severe acute kidney injury following a cardiac arrest: A prospective multicentre study. Resuscitation. 2019. PMID: 31216431. doi:10.1016/j.resuscitation.2019.06.008
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。